

Enduring Materials Learner Notification

City of Hope- Department of Clinical Cancer Genomics

Cancer Genomics Training and Education for VA Providers – Bundle #4: Tumor/Germline Testing

Date of CE Release: December 13, 2024

Date of CE Expiration: December 13, 2025

Location: Online

Acknowledgement of Financial Commercial Support

No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles and complete an evaluation form to receive a certificate of completion. You must attend the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and City Of Hope. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Amedco Joint Accreditation #4008163.

Professions in scope for this activity are listed below.

Physicians

Amedco LLC designates this live activity for a maximum of **2.25 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists and Pharmacy Technicians

Amedco LLC designates this activity for a maximum of **2.25** knowledge-based CPE contact hours.

UAN: JA4008163-9999-24-259-H01-P / JA4008163-9999-24-259-H01-T

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.

American Board of Surgery (ABS) MOC



Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the **CME** requirements of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit. Up to **2.25 CME for MOC** hours available.

You must request your certificate within 45 days of the activity to meet the deadline for submission to PARS. Credits are generally reported during the first week of each month for those who claimed during the month prior.

Objectives - After Attending This Program You Should Be Able To

1. Describe the differences between a high, moderate, and low penetrance cancer susceptibility gene.
2. Counsel a patient about moderate and low penetrance cancer susceptibility genes found on routine clinical testing.
3. Compare the benefits and challenges of somatic panel, germline panel and paired somatic/germline sequencing.
4. Identify issues related to incidental findings in cancer sequencing.
5. Review the various possible mechanisms of both germline and somatic mosaicism.
6. Identify the various mechanisms that can be associated with an altered allelic fraction in a germline genetic test.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First	Last	Commercial Interest
Jill	Bates	NA
Mary Jane	Berry	NA
Kathleen	Blazer	Astra Zeneca:Research Grant Overall Principal Investigator
Kelly	Bolton	Servier:Research Grant Overall Principal Investigator,Servier:Scientific/Medical Advisory Board Member
ALEXANDRA	CAPASSO	NA
Anuja	Chitre	NA
Jane	Churpek	UpToDate, Inc:Other
Julie	Culver	NA
Madeline	Currey	NA
Sandra	Dreike	NA
Hunaydah	Elfarawi	NA
Tobias	Else	MERCK:Scientific/Medical Advisory Board Member
Christina	Fujii	NA
Lauren	Gima	NA
Veda	Giri	NA
Stacy	Gray	Harvard Medical School:Consultant
Heather	Hampel	GI OnDemand:Consultant,GI OnDemand:Other,Genome Medical:Private Stock Shareholder,Exact Sciences:Scientific/Medical Advisory Board Member,LS CancerDiag OY:Scientific/Medical Advisory Board Member
Gregory	Idos	NA
Joanne	Jeter	NA
Jesse	Kasten	NA
Elisabeth	King	NA
Sonia	Kupfer	Myriad:Other,Invitae:Other,PRECEDE:Other
Allison	Kurian	Ambry Genetics:Other,Myriad Genetics:Other
Phyllis	Leung	NA
Regine	Lim	Sema4/GeneDx:Employee
John	Luna	NA
Lisa	Madlensky	VieCure:Scientific/Medical Advisory Board Member
Rachelle	Manookian	NA
Luke	McCorkel	NA
Carolyn	Menendez	NA
Ashley	Mochizuki	NA
Bruce	Montgomery	AstraZeneca:Research Grant Overall Principal Investigator,Janssen:Research Grant Site Principal Investigator,Beigene:Research Grant Site Principal Investigator,Astellas:Research Grant Site Principal Investigator
Bitu	Nehoray	NA
Gloria	Nunez	NA
Wai	Park	NA
Colin	Pritchard	NA
Padma	Rajagopal	NA
Kathryn	Reyes	NA
Christina	Rybak	Natera:Public Stock Shareholder
Marvin	Rydberg	NA
Tracy	Sandstrom	NA
Susan	Shehayeb	NA
Brian	Shuch	NA
Elise	Sobotka	NA
Ilana	Solomon	NA
Dev	Tanna	NA
Michelle	Weaver Knowles	Myriad Genetics:Speakers Bureau,Ambry Genetics:Speakers Bureau,Merck :Speakers Bureau
Kaila	Wilson	NA
a	Zukin	NA